NEW YORK, NY, USA I July 28, 2015 I Dipexium Pharmaceuticals, Inc. (DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), today announced that new Locilex® microbiology data will be presented at the American Society for Microbiology’s Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy’s International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific meeting in San Diego, California, September 17-21, 2015.
Dipexium and its research collaborators, will present data on pexiganan, the active pharmaceutical ingredient in Locilex®, that highlight pexiganan’s activity against a broad spectrum of bacteria resistant to seven marketed or investigational topical antimicrobials.
Poster Title: In Vitro Activity of Pexiganan Tested Against Pathogens with Elevated MICs to Topical Antimicrobials
Poster Board Number: F-730
Date and Time: Saturday, September 19, 11 a.m. – 1 p.m. PT
Session / Location: Poster Session 095: Antimicrobial Peptides / Exhibit Hall F
A copy of the ICAAC/ICC poster presentation will be uploaded to Dipexium’s website at 11 a.m. PT on the day of the presentation.
About ICAAC/ICC (www.icacc.org)
ICAAC/ICC, the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers from around the world. With over 60% of its attendees living outside of the United States, ICAAC provides a rare opportunity to bring together the field’s foremost leaders to discuss the state of infection control and prevention on a global scale. Through oral and poster presentations, 10,000 physicians, clinical microbiologists, researchers, and pharmacists will come together to share their research, discover the latest breakthroughs, and work towards fostering global solutions to the problems of infectious diseases and antimicrobial agents.
About Dipexium Pharmaceuticals, Inc.
Dipexium Pharmaceuticals, Inc. (DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of Mild DFI. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). For more information, visit www.dipexiumpharmaceuticals.com.
SOURCE: Dipexium Pharmaceuticals
Post Views: 63
NEW YORK, NY, USA I July 28, 2015 I Dipexium Pharmaceuticals, Inc. (DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), today announced that new Locilex® microbiology data will be presented at the American Society for Microbiology’s Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy’s International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific meeting in San Diego, California, September 17-21, 2015.
Dipexium and its research collaborators, will present data on pexiganan, the active pharmaceutical ingredient in Locilex®, that highlight pexiganan’s activity against a broad spectrum of bacteria resistant to seven marketed or investigational topical antimicrobials.
Poster Title: In Vitro Activity of Pexiganan Tested Against Pathogens with Elevated MICs to Topical Antimicrobials
Poster Board Number: F-730
Date and Time: Saturday, September 19, 11 a.m. – 1 p.m. PT
Session / Location: Poster Session 095: Antimicrobial Peptides / Exhibit Hall F
A copy of the ICAAC/ICC poster presentation will be uploaded to Dipexium’s website at 11 a.m. PT on the day of the presentation.
About ICAAC/ICC (www.icacc.org)
ICAAC/ICC, the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers from around the world. With over 60% of its attendees living outside of the United States, ICAAC provides a rare opportunity to bring together the field’s foremost leaders to discuss the state of infection control and prevention on a global scale. Through oral and poster presentations, 10,000 physicians, clinical microbiologists, researchers, and pharmacists will come together to share their research, discover the latest breakthroughs, and work towards fostering global solutions to the problems of infectious diseases and antimicrobial agents.
About Dipexium Pharmaceuticals, Inc.
Dipexium Pharmaceuticals, Inc. (DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of Mild DFI. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). For more information, visit www.dipexiumpharmaceuticals.com.
SOURCE: Dipexium Pharmaceuticals
Post Views: 63
